Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc.: Was the decision to selectively present evidence of commercial success too “clever by half”?

In Bayer Healthcare Pharmaceuticals, Inc. et al. v. Watson Pharmaceuticals, Inc. et al. 713 F.3d 1369 (Fed. Cir. 2013), the Federal Circuit reversed the District Court's grant of summary judgment and found the asserted patent claims obvious in view of the cited prior art. Neither the Federal Circuit nor the District Court addressed the issue of commercial success despite the fact that the patentee had submitted evidence of commercial success in its opposition to Defendants' motion for summary judgment (but not in support of its own motion for summary judgment). This case report presents the decision of the District Court, the arguments made to the Federal Circuit by the parties and how the Federal Circuit addressed these issues. [ABSTRACT FROM AUTHOR]